RxDoctor Payments Data

Alin Ledford, MD

Family Medicine · Keaau, HINPI 1972716348

Payments from drug & device makers

$1,932in general payments, 2019–2025

Across 78 payments — averaging $24.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$845
  • Lilly USA, LLC$212
  • AbbVie$187
  • Novo Nordisk$166
  • Amarin Pharma, Inc.$155
  • Pfizer$116
  • plus $251 from 8 others

What the payments were for

  • Food & beverage$1,927100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,932 in reported general payments places this provider in the 80th percentile of 376 family medicine providers in Hawaii.

See all family medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$53,299
Medicare patients
78
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast20$107,165
OzempicSemaglutide68$82,127
EliquisApixaban41$30,925
TrulicityDulaglutide15$29,965
ProliaDenosumab13$23,163
JanuviaSitagliptin Phosphate11$18,568
JardianceEmpagliflozin12$11,356
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen207$7,314
Breo ElliptaFluticasone/Vilanterol12$4,979
Albuterol Sulfate HfaAlbuterol Sulfate115$3,638
Pregabalin84$3,447
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen68$2,896
Cyclobenzaprine Hcl132$2,889
Atorvastatin Calcium128$2,616
Wixela InhubFluticasone Propion/Salmeterol28$2,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Prolia$845$130,32833 claims
Novo NordiskOzempic$166$82,12768 claims
PfizerEliquis$116$30,92541 claims
Lilly USA, LLCTrulicity$212$29,96515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 376 family medicine providers in Hawaii.

Other family medicine in Keaau

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →